Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
about
Current Trends of Renal Impairment in Multiple MyelomaImpact of High-Cut-Off Dialysis on Renal Recovery in Dialysis-Dependent Multiple Myeloma Patients: Results from a Case-Control StudyTherapeutic Efficacy and Cost Effectiveness of High Cut-Off Dialyzers Compared to Conventional Dialysis in Patients with Cast Nephropathy.European Myeloma Network guidelines for the management of multiple myeloma-related complications.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Managing renal complications in multiple myeloma.Current treatments for renal failure due to multiple myeloma.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1.Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
P2860
Q26740444-84635C3E-F8C4-4A95-92F1-3AA4DD4CB8CCQ36010511-1EAE0317-C1FE-4C68-8C7E-6AC9E3BF9B18Q36088601-0B2B3CFC-8064-43FC-AD04-C3204E72E49CQ36115636-278F5BC7-39F5-40FB-8CB8-6E8E9E40AFD2Q37644252-5410D60C-F32B-42A7-89D7-F94E74A6445CQ38900024-9A5BC2E6-050B-4AAA-83DD-44BF82A72D36Q38959138-FCFBC4C6-2D56-4198-A864-3872C647941DQ38976968-C67DEBCC-A4A5-4E80-A986-12476640C993Q39273146-9B407EB3-D599-4A4D-B221-810ACA918E03Q42376166-43718481-5558-4CB1-82D3-FAAA62FE9A39Q47162496-2094A73C-E475-472F-A747-693DF7F00E9CQ47794767-2A278919-8AAB-4A5A-A713-585143432BCEQ50055765-038BBC9C-AAEA-4223-82D4-51E81E5FB426Q50089740-856362C4-297C-44C0-91CC-FBB6DCF96A7E
P2860
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Bortezomib-based therapy combi ...... with severe renal impairment.
@en
Bortezomib-based therapy combi ...... with severe renal impairment.
@nl
type
label
Bortezomib-based therapy combi ...... with severe renal impairment.
@en
Bortezomib-based therapy combi ...... with severe renal impairment.
@nl
prefLabel
Bortezomib-based therapy combi ...... with severe renal impairment.
@en
Bortezomib-based therapy combi ...... with severe renal impairment.
@nl
P2093
P2860
P50
P356
P1476
Bortezomib-based therapy combi ...... s with severe renal impairment
@en
P2093
Annalisa Pezzi
Antonio Santoro
Beatrice Anna Zannetti
Carolina Terragna
Elena Mancini
Elena Zamagni
Giulia Marzocchi
Lucia Barbara De Sanctis
Lucia Pantani
Marisa Santostefano
P2860
P304
P356
10.1002/AJH.24035
P577
2015-07-01T00:00:00Z